Attendee search 

Pharma and diagnostics

PepLib is rethinking peptide drug discovery: a revolutionary platform technology company with a proprietary peptide library, unique screening capabilities, and robust internal drug development programs. PepLib’s novel peptide technology platform uses cyclic peptides to encode and compress half of a billion sequences, including complete peptide libraries up to pentapeptides (ZSenithFive™). PepLib’s platform, powered by Peptide Information Compression Technology (PICT), is capable of high-sensitivity and high-specificity drug mining for a broad spectrum of targets, including membrane-proteins. Intelligently designed, individually isolated and packed peptides in HTS well format support functional assays, including cell-based assay and in vivo assay. PepLib has validated the efficiency of the platform on the well-studied PD-1/PD-L1 model and through their partnerships with multiple pharmaceutical companies and internal development programs in oncology, pain, metabolic disorders, and antimicrobials/antivirals, including COVID. Formed by leading scientists in peptide chemistry and biosynthesis with a combined 75 years of biopharmaceutical R&D experience, PepLib hopes to leverage its innovative platform to advance peptide drug discovery for the global biopharmaceutical community.

TIF is a VC investor specializing in early stage biotech companies in China.

www.tsinghua-sz.org/www.leaguer.com.cn

OP Financial Limited (1140.HK) is a cross-border and cross-sector investment company that listed on the main board of the Stock Exchange of Hong Kong Limited. OP Financial has strong capability of investment, financing and industry consolidation, while its investment portfolios cover many listed and unlisted company across geographies and industries. According to the investment cycle, OP Financial builds cross-cycle portfolios with long-term core holding companies, medium-term private equity and venture capital funds and short-term arbitrage project, which are tailored to create steady returns for the shareholders.

Zhejiang Jianfeng Pharmaceutical Co., Ltd., founded on Dec. 30th, 1998, is a wholly-owned subsidiary of listed company Zhejiang Jianfeng Group Co., Ltd. (SHA: 600668). 　　Our company consists of five industrial enterprises, three commercial enterprises, three scientific institutions and two mobile postdoctoral stations. It is one of National Top 100 Pharmaceutical Enterprises, one of Top 10 Pharmaceutical Industrial Enterprises of Zhejiang Province, National Key High-tech Enterprise, National high-tech Industrialization Demonstration Project Enterprise, Innovative Demonstration Enterprise of Zhejiang Province, and AAA-level Contract-honoring and Promise-keeping Enterprise of Zhejiang Province.

Our key products include Aspartic Acid Amlodipine Tablets, Aceclofenac Sustained-release Tablets, Paroxetine Hydrochloride Tablets, Cefmenoxime Hydrochloride for Injection, Yufeng Ningxin Drop Pills, Penciclovir for Injection, Sodium Hyaluronate Eye Drops, and etc.

Adhering to the corporate spirit of “Aiming for Top One, Producing Fine Medicine”, pursuing business philosophy of “science and technology achieve health”, our company has been oriented by the development of bulk pharmaceutical chemicals with high technology content and high-added value, and new chemical medicine preparations and aided by the natural products extraction and proprietary Chinese medicine preparations. Meanwhile, our company is paying attention to the development method of new biological agent medicine, and will enter into the health product field in good time. We now have a main line with three major series products, which are anti-infection medicine, cardiovascular medicine, and anti-depression medicine. Depending on first-rate business philosophy, first-rate production management and first-rate products, our company will create a famous brand that is trusted by the public, and contribute to the health of human.

CPE is a leading alternative asset manager, with asset classes spanning private equity, mezzanine and the public market. Founded in 2008 by a world class team of investment professionals and supported by over 200 domestic and international investors, CPE knows China like no one else and is a globally minded long-term value investor. The firm uses its sector expertise to generate deal flow and drive the value creation work during the post-investment stage. CPE follows a disciplined investment approach to preserve and grow its investors’ capital. The firm’s private equity portfolio of more than 100 companies is highly diversified by sector and stage of investment. CPE takes pride in its forward-looking investment philosophy and works hard to create value over the long-term for its investors and a better world.

IHM-GBA is an investor and an innovation center in Guangzhou, China. The firm is looking to invest in the medical device sector. The firm is highly focusing on investment and cooperation in high-performance innovative medical device companies. The firm also helps companies to enter the Chinese market.

Convalife is an innovative, research-based, clinical stage biopharmaceutical company focused on bringing innovative therapies to patients with cancer, autoimmune and infectious diseases in China and around the world.

Foucus on R&D Small moleculer anti oncology and inmuno-oncology.